Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Manal F. Abdelmalek, Jeongeun Hyun, Steven R. Patierno, Rebecca Caffrey, Cynthia A. Moylan, Muthana Al Abo, Anna Mae Diehl, Xiyou Zhou, Seh-Hoon Oh, Arun J. Sanyal, Kun Xiang, Rajesh Kumar Dutta, Raquel Maeso-Díaz, Jennifer A. Freedman
Publikováno v:
J Hepatol
Background & Aims Non-alcoholic fatty liver disease (NAFLD), the hepatic correlate of the metabolic syndrome, is a major risk factor for hepatobiliary cancer (HBC). Although chronic inflammation is thought to be the root cause of all these diseases,
Autor:
Colby Ayers, Kara Wegermann, Vanessa Blumer, Robert W. McGarrah, Ambarish Pandey, Cynthia A. Moylan, Anna Mae Diehl, Tarek Bekfani, Anthony E. Peters, Manal F. Abdelmalek, Marat Fudim, Justin L. Grodin
Publikováno v:
ESC Heart Failure, Vol 8, Iss 2, Pp 842-848 (2021)
ESC Heart Failure
ESC Heart Failure
Aims Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liv
Autor:
Sven Francque, Manal F. Abdelmalek, Veronica Miller, Claudia Filozof, Elmer Schabel, Katherine Barradas, Mazen Noureddin, Mark Berner-Hansen, Jörn M. Schattenberg, Stephanie O Omokaro, Oliver Glass
Publikováno v:
Journal of hepatology
Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to
Autor:
Elizabeth K. Fletcher, Athan Kuliopulos, Nga Nguyen, Srijoy Guha, Andrew Shearer, Daniel H. Cox, James D. Baleja, Ying Wang, Manal F. Abdelmalek, Lidija Covic, Rajashree Rana
Publikováno v:
Molecular Metabolism, Vol 29, Iss, Pp 99-113 (2019)
Molecular Metabolism
Molecular Metabolism
Objective Increases in hepatic and plasma cholesterol occur in patients with nonalcoholic fatty liver disease (NAFLD), although the reason for this is not well understood. We investigated whether Protease-Activated Receptor 2 (PAR2) plays a role in c
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an
Autor:
Robert H. Eckel, Leon A. Adams, Christos S. Mantzoros, Kenneth Cusi, Stephen A. Harrison, Fasiha Kanwal, Eugene E. Wright, Vincent Wai-Sun Wong, Hashem B. El-Serag, Rohit Loomba, Elisabetta Bugianesi, Manal F. Abdelmalek, Lee M. Kaplan, Kim Pfotenhauer, Jay H. Shubrook
Publikováno v:
Gastroenterology, vol 161, iss 5
Gastroenterology
Gastroenterology
Find AGA's NASH Clinical Care Pathway Appfor iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approx
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
Sven Francque, Frank M. Sacks, Michael Roden, Jean-François Dufour, Frank Tacke, Christopher D. Byrne, Gyongyi Szabo, Kenneth Cusi, Manal F. Abdelmalek
Publikováno v:
Nature Reviews Gastroenterology and Hepatology
The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the
Autor:
Stephen J. Rossi, Mary E. Rinella, Mark J. Jaros, Alex M. DePaoli, Marcelo Kugelmas, Stephen A. Harrison, Manal F. Abdelmalek, Hays Arnold, James F. Trotter, Mustafa R. Bashir, ing L, Angelo H. Paredes, Rohit Loomba
Publikováno v:
The Lancet. 391:1174-1185
Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug Administration (FDA)-approved treatment exists. FGF19 is a hormone that r
Autor:
Kara Wegermann, Ayako Suzuki, Alisha M. Mavis, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan
Publikováno v:
Hepatology. 73:1625-1625
We appreciate de Zegher and Ibanez calling attention to the association between non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). As de Zegher and Ibanez rightly point out, NAFLD can occur in children and adolescents w